Drug intelligence / Profile preview

MMFS-205

Development stage: Preclinical
Lead developer: Neurocentria
Modality: Small Molecules
Administration: Oral

Overview

MMFS-205 is a novel investigational synapse density enhancer, structurally related to and in the same class as MMFS-01 (magnesium L-threonate-based compounds), proposed for the improvement of cognitive function and global outcomes in patients with early Alzheimer's disease or mild cognitive impairment. Like MMFS-01, it is believed to act primarily by increasing brain magnesium levels, which in turn enhances synaptic density and plasticity. Its mechanism addresses multiple molecular pathways implicated in cognitive decline, such as mitochondrial function, synaptic marker expression, and neuronal outgrowth. The compound is being developed as a small molecule for oral administration.

Brand names: MMFS-205MMFS205MMFS 205
Other names: MMFS-205MMFS205MMFS 205

Beyond the preview

Go deeper on MMFS-205.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MMFS-205.

Explore the full profile